Oral Session Breast Cancer localized disease!; ◽De-escalation of HER2-positive neoadjuvant therapy. ◽Withdrawing Carboplatin from the TCHP regimen had non-inferior RPC rates and survival outcomes! OncoAlert #ASCO25 ASCO #BreastCancer #bcsm

🚨 Proud to be part of #IUCS25 alongside such outstanding colleagues! 📍 Join us in Portsmouth or online – Sept 4-5 🎟️ Free in-person registration 🤝🎓 Engage with top minds in #GUonc 📢 Abstract & travel grant deadline: June 30 🔗 Register: urologycancersummit.org/registration 🔗 Submit:

Excited to share that I will be joining Winship Cancer Institute of Emory University (Atlanta, GA) as a GI/NET Medical Oncologist. I feel fortunate to finally have the opportunity to live the dream of caring for patients with GI and neuroendocrine cancers. Grateful to mentors and colleagues UI Holden Comprehensive Cancer Center for

Great start to the weekend with Kidney Cancer 81K Houston walk with MD Anderson Cancer Center in honor of those who will diagnosed with kidney cancer this year. Appreciate everyone who came out and walked in the heat Mohammad Jad Moussa, MD, MSc Eleonora Dondossola,PhD Pavlos Msaouel and the bone mets lab.

"Outcomes of PeIN at the surgical margin: insights from an organ-sparing penile cancer database". Highly clinically relevant question I am often asked about in terms of management. ncbi.nlm.nih.gov/pubmed/40478443

🚨Deadline Alert TOMORROW‼️ 📅 Tuesday, June 10 #ASCOQLTY25 Abstract submissions are due this week! Share your solutions-driven research & help shape the future of quality cancer care. Don’t miss the premier forum for innovation in care delivery! 👉 asco.org/quality

Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study - ScienceDirect sciencedirect.com/science/articl…

Current status of adiuvant #immunotherapy in #RCC: a Delphi study coordinated by Bernard Escudier. Full article here: doi.org/10.1016/j.ejca… #CancerResearch #oncology #genitourinary #RCC #Immunotherapy

UCSD GU Medical Oncology is looking for the next academic medical oncologist to join our group! Amazing to see this program continue to blossom. The sky is the limit! ⁦Toni Choueiri, MD⁩ ⁦Neeraj Agarwal, MD, FASCO⁩ ⁦UroToday.com⁩ ⁦OncoAlert⁩ ⁦ apol-recruit.ucsd.edu/JPF04302

A New Therapeutic Approach May Make Waves in Kidney Cancer Treatment Michael Serzan, MD Dana-Farber Dana-Farber News #Oncology #MedEd #KidneyCancer curetoday.com/view/a-new-the…

Grateful to CURE Today to highlight #STELLAR002 novel doublet/triplet #Zanza + #Nivo +/- #RELA (LAG3) in 1L ccRCC 📌 Doublet/triplet favorable AE profiel w/ 5-18% d/c rate 📌 #Zanza + Nivo +/- Rela led to DCR 90% and 12mo PFS 58-64% Outstanding questions: ❓What is role of

An absolute stellar GU oncology section. Looking esp for interest in #GCT! Great team! Great science! Great patient care! And an amazing place to live! Dr. Darren Feldman Nabil Adra Memorial Sloan Kettering Cancer Center IU Simon Comprehensive Cancer Center Uromigos DrTylerStewart

Should be some interesting discussions tomorrow including EPIC results, vaccinations, and QoL in #penilecancer #baus25

Just in Clinical Cancer Research 👉Congrats Chadi Hage Chehade Umang Swami & GU Cancer Research Program @HuntsmanCancer team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 Flatiron Health Foundation Medicine Ryon Graf, PhD 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i OncoAlert UroToday.com

Zanzalintinib + nivolumab showed encouraging effectiveness and acceptable tolerability in previously untreated stage 4 #RCC, according to initial data from an expansion cohort of the STELLAR-002 study. #kcsm | jc Moffitt Cancer Center Moffitt Research hubs.li/Q03sc8DT0

With the disappointing announcement today by AbbVie of the negative result of the VERONA venetoclax/azacitidine trial, that brings the tally to (by my count) 17 consecutive negative randomized drug trials in higher-risk #MDSsm. This is a slide I made summarizing them./1

Excited to see our work published in Clinical Cancer Research ! Real-world pts w/ mHSPC #prostatecancer w/ HRRalt had worse survival than those w/ non-altered HRR 👉bit.ly/3TsOw9i👇 Grateful for terrific support from team Ryon Graf, PhD Umang Swami Neeraj Agarwal, MD, FASCO UroToday.com OncoAlert

‼️🚨Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer a new SOC ⁦NEJM⁩ nejm.org/doi/full/10.10…

🚨 Adding neoadjuvant + adjuvant #pembrolizumab to standard care improves 3-yr event-free survival in locally advanced #HNSCC (KEYNOTE-689) 🧠⚔️ ✅ EFS 59.8% vs 45.9% (CPS ≥10) 📉 HR 0.66, p=0.004 No impact on surgery rates. ⁦NEJM⁩ nejm.org/doi/full/10.10…

🚨 New SOC In low-risk differentiated #thyroidcancer, no radioiodine ablation post-surgery was non-inferior to ablation for 5-year recurrence-free survival (97.9% vs 96.3%). 🌟 Less treatment, same outcome. 📉 Fewer side effects. 💸 Lower cost ⁦ thelancet.com/journals/lance…